The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth
Open accessAbstract
Despite abundant evidence that aberrant Rho-family GTPase activation contributes to most steps of cancer initiation and progression, there is a dearth of inhibitors of their effectors (e.g., p21-activated kinases). Through high-throughput screening and structure-based design, we identify PF-3758309, a potent (K d = 2.7 nM), ATP-competitive, pyrrolopyrazole inhibitor of PAK4. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC 50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC 50 = 4.7 ± 3 nM). The molecular underpinnings of PF-3758309 biological effects were characterized using an integration of traditional and emerging technologies. Crystallographic characterization of the PF-3758309/PAK4 complex defined determinants of potency and kinase selectivity. Global high-content cellular analysis confirms that PF-3758309 modulates known PAK4-dependent signaling nodes and identifies unexpected links to additional pathways (e.g., p53). In tumor models, PF-3758309 inhibits PAK4-dependent pathways in proteomic studies and regulates functional activities related to cell proliferation and survival. PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC 50 value of 0.4 nM in the most sensitive model. This study defines PAK4-related pathways, provides additional support for PAK4 as a therapeutic target with a unique combination of functions (apoptotic, cytoskeletal, cell-cycle), and identifies a potent, orally available small-molecule PAK inhibitor with significant promise for the treatment of human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009
Rho GTPases in cancer cell biology
Vega, F. M., & Ridley, A. J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.039 · Cited by 779
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
miR-29 miRNAs activate p53 by targeting p85α and CDC42
Park, S.-Y., Lee, J. H., Ha, M., Nam, J.-W., & Kim, V. N. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1533 · Cited by 606
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
A role for Rho in Ras transformation
Qiu, R. G., Chen, J., McCormick, F., & Symons, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11781 · Cited by 533
Sahai, E. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.755 · Cited by 384
Arias‐Romero, L. E., & Chernoff, J. (2008) · Biology of the Cell · doi:10.1042/bc20070109 · Cited by 364
Abo, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6527 · Cited by 355
Rho family proteins and Ras transformation: the RHOad less traveled gets congested
Zohn, I. M., Campbell, S. L., Khosravi-Far, R., Rossman, K. L., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202181 · Cited by 352
Imaging of Cell Proliferation: Status and Prospects
Bading, J. R., & Shields, A. F. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046391 · Cited by 320
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Identifying off-target effects and hidden phenotypes of drugs in human cells
MacDonald, M. L., Lamerdin, J., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., Yu, H., Dias, J., Minami, T., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio790 · Cited by 293
Self-citationRho GTPases: functions and association with cancer
Ellenbroek, S. I. J., & Collard, J. G. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9119-1 · Cited by 289
Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines
Callow, M. G., Clairvoyant, F., Zhu, S., Schryver, B., Whyte, D. B., Bischoff, J. R., Jallal, B., & Smeal, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105732200 · Cited by 288
Self-citationRecognizing and exploiting differences between RNAi and small-molecule inhibitors
Weiss, W. A., Taylor, S. S., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio1207-739 · Cited by 283
Dan, C., Kelly, A., Bernard, O., & Minden, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100871200 · Cited by 278
Pak protein kinases and their role in cancer
Dummler, B., Ohshiro, K., Kumar, R., & Field, J. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9168-1 · Cited by 259
Molli, P. R., Li, D. Q., Murray, B. W., Rayala, S. K., & Kumar, R. (2009) · Oncogene · doi:10.1038/onc.2009.119 · Cited by 258
Self-citationSwami, S., Raghavachari, N., Muller, U. R., Bao, Y. P., & Feldman, D. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024487118457 · Cited by 205
The Serine/Threonine Kinase PAK4 Prevents Caspase Activation and Protects Cells from Apoptosis
Gnesutta, N., Qu, J., & Minden, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011046200 · Cited by 200
PAK4 mediates morphological changes through the regulation of GEF-H1
Callow, M. G., Zozulya, S., Gishizky, M. L., Jallal, B., & Smeal, T. (2005) · Journal of Cell Science · doi:10.1242/jcs.02313 · Cited by 169 · cited 17×
“In this system, PAK4 phosphorylates GEF-H1 on a previously characterized serine residue 810 (21) and is inhibited by PF-3758309 (IC50= 1.3± 0.5 nM).”
BackgroundInfluentialSelf-citationActivated PAK4 Regulates Cell Adhesion and Anchorage-Independent Growth
Qu, J., Cammarano, M. S., Shi, Q., Ha, K. C., de Lanerolle, P., & Minden, A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3523-3533.2001 · Cited by 166
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer
Kimmelman, A. C., Hezel, A. F., Aguirre, A. J., Zheng, H., Paik, J.-H., Ying, H., Chu, G. C., Zhang, J. X., Sahin, E., Yeo, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809966105 · Cited by 163
Control of cell migration: a tumour suppressor function for p53?
Roger, L., Gadéa, G., & Roux, P. (2006) · Biology of the Cell · doi:10.1042/bc20050058 · Cited by 156
Copy number alterations in pancreatic cancer identify recurrentPAK4amplification
Chen, S., Auletta, T., Dovirak, O., Hutter, C., Kuntz, K., El‐ftesi, S., Kendall, J., Han, H., Hoff, D. D. V., Ashfaq, R., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.11.6840 · Cited by 150
UnPAKing the class differences among p21-activated kinases
Eswaran, J., Soundararajan, M., Kumar, R., & Knapp, S. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.06.002 · Cited by 140
Mahlamäki, E., Kauraniemi, P., Monni, O. M., Wolf, M., Hautaniemi, S., & Kallioniemi, A. H. (2004) · Neoplasia · doi:10.1593/neo.04130 · Cited by 131
Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases
(2008) · Methods in Enzymology · doi:10.1016/s0076-6879(07)00409-0 · Cited by 126 · cited 1×
“One such area is Rho GTPase signaling, which has been hard to directly target (2) despite the extensive experimental evidence of its role in most aspects of cancer initiation and progression including uncontrolled proliferation, evasion of apoptosis, actin cytoskeletal remodeling, invasion, and metastasis (3–8).”
BackgroundEswaran, J., Lee, W. H., Debreczeni, J. E., Filippakopoulos, P., Turnbull, A., Fedorov, O., Deacon, S. W., Peterson, J. R., & Knapp, S. (2007) · Structure · doi:10.1016/j.str.2007.01.001 · Cited by 126
Gnesutta, N., & Minden, A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7838-7848.2003 · Cited by 109
Coatomer-bound Cdc42 regulates dynein recruitment to COPI vesicles
Chen, J., Fucini, R. V., Lacomis, L., Erdjument‐Bromage, H., Tempst, P., & Stamnes, M. A. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501157 · Cited by 107
Ste20-Type Kinases: Evolutionarily Conserved Regulators of Ion Transport and Cell Volume
Strange, K. B., Denton, J. S., & Nehrke, K. W. (2006) · Physiology · doi:10.1152/physiol.00139.2005 · Cited by 105
Li, X., & Minden, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506884200 · Cited by 87
Targeting group II PAKs in cancer and metastasis
Eswaran, J., Soundararajan, M., & Knapp, S. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9181-4 · Cited by 82
Cammarano, M. S., Nekrasova, T., Noel, B., & Minden, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9532-9542.2005 · Cited by 79
Apisarnthanarax, S., Alauddin, M. M., Mourtada, F., Ariga, H., Raju, U., Mawlawi, O. R., Han, D., Bornmann, W. G., Ajani, J. A., Milas, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2720 · Cited by 76
Essential role for the Pak4 protein kinase in extraembryonic tissue development and vessel formation
Tian, Y., Lei, L., Cammarano, M. S., Nekrasova, T., & Minden, A. (2009) · Mechanisms of Development · doi:10.1016/j.mod.2009.05.002 · Cited by 60
ARF1-mediated actin polymerization produces movement of artificial vesicles
Heuvingh, J., Franco, M., Chavrier, P., & Sykes, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704749104 · Cited by 50
Targeting the unactivated conformations of protein kinases for small molecule drug discovery
Alton, G., & Lunney, E. A. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.595 · Cited by 33
Francone, T. D., Landmann, R., Chen, C., Sun, M. Y., Kuntz, E. J., Zeng, Z., DeMatteo, R. P., Paty, P. B., & Weiser, M. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0466 · Cited by 32
Grant, S. K., Tran, P., Zhang, Q., Zou, A., Dinh, D. M., Jensen, J. R., Zhou, S., Kang, X., Zachwieja, J., Lippincott, J., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.029 · Cited by 11
Cited by
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
PAK signalling during the development and progression of cancer
Radu, M., Semenova, G., Kosoff, R., & Chernoff, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3645 · Cited by 503
Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases
Zhao, S., Wang, R., Song, S., Hao, D., Han, G., Song, X., Zhang, J., Pizzi, M. P., Shanbhag, N., Futreal, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106913 · Cited by 5
Metadata
- Authors
- Murray, B. W., Guo, C., Piraino, J., Westwick, J. K., Zhang, C., Lamerdin, J., Dagostino, E., Knighton, D., Loi, C.-M., Zager, M., Kraynov, E., Popoff, I., Christensen, J. G., Martinez, R., Kephart, S. E., Marakovits, J., Karlicek, S., Bergqvist, S., & Smeal, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-05-03
- Volume
- 107
- Issue
- 20
- Pages
- 9446-9451
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2052795297
- Cited by
- 325
- References
- 42
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.